In April of 2014, the Food and Drug Administration advisory committee voted unanimously 14 – 0 against recommending that the agency approve Moxduo. Moxduo is the first drug to combine morphine and oxycodone into one capsule. The decision was based on the grounds that QRxPharma had not proved Moxduo is less likely to cause potentially life-threatening respiratory suppression than taking morphine or oxycodone alone. On May 1, 2014, QRxPharma Replaced their CEO in response to the setback. Dr Edward Rudnic, former QRxPharma COO since early 2012, publicly stated, “To this end, we are postponing submission of the Moxduo Marketing Authorization Application in Europe and evaluating the regulatory paths with our strategic collaborations in other jurisdictions.” Las Vegas Recovery Center’s Medical Director, Mel Pohl, MD, FASAM responds: “I am guardedly optimistic. I doubt that anyone would dispute the fact that WE DONT NEED ANY NEW OPIOIDS on the market. Perhaps sanity has returned to the FDA’s approval process unlike what occurred with Zohydro.”